Alivus Life Sciences (NSE:ALIVUS) Total Liabilities: ₹6,508 Mil (As of Mar. 2026)


NSE:ALIVUS Alivus Life Sciences Ltd NSE:ALIVUS
85 GF Score
Price ₹1,160.10
GF Value ₹1,007.38
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Alivus Life Sciences Total Liabilities?

Alivus Life Sciences NSE:ALIVUS +1.50% 85 Total Liabilities is ₹6,508 Mil as of Mar. 2026. GuruFocus rates NSE:ALIVUS with a GF Score™ of 85/100 and a GF Value™ of ₹1,007.38 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Alivus Life Sciences's Total Liabilities for the quarter that ended in Mar. 2026 was ₹6,508 Mil.

Alivus Life Sciences's quarterly Total Liabilities declined from Sep. 2025 (₹6,229.87 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹6,507.65 Mil).

Alivus Life Sciences's annual Total Liabilities increased from Mar. 2024 (₹5,180.90 Mil) to Mar. 2025 (₹5,940.81 Mil) and increased from Mar. 2025 (₹5,940.81 Mil) to Mar. 2026 (₹6,507.65 Mil).

Alivus Life Sciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Alivus Life Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences Total Liabilities Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial 4,166.95 5,639.40 5,180.90 5,940.81 6,507.65

Alivus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,940.81 0.00 6,229.87 0.00 6,507.65
NSE:ALIVUS
85GF Score
Alivus Life Sciences Ltd NSE:ALIVUS
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alivus Life Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alivus Life Sciences's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5080.35+(487.94+939.36
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6,508

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=39828.97-33321.32
=6,508

Alivus Life Sciences's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5080.35+(487.94+939.36
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6,508

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=39828.97-33321.32
=6,508

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹6,508 Mil mean?
Alivus Life Sciences (NSE:ALIVUS) has a Total Liabilities of ₹6,508 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alivus Life Sciences and its competitors.
Is Alivus Life Sciences' Total Liabilities too high?
Alivus Life Sciences' current Total Liabilities is ₹6,508 Mil. Overall, Alivus Life Sciences has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Total Liabilities compare to ZTS and UTHR?
Alivus Life Sciences' Total Liabilities of ₹6,508 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alivus Life Sciences and its competitors. Alivus Life Sciences's current Total Liabilities is ₹6,508 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,007.38, compared to a current price of ₹1,160.10 — trading 15.2% above its estimated fair value. The current Total Liabilities is ₹6,508 Mil. Alivus Life Sciences' overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Total Liabilities is ₹6,508 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,160.10 is trading 15.2% above its estimated GF Value™ of ₹1,007.38. GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.

Key valuation signals for NSE:ALIVUS:

  • Total Liabilities: ₹6,508 Mil
  • GF Value™: ₹1,007.38 vs. price of ₹1,160.10 (15.2% above fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alivus Life Sciences Business Description

Other Exchanges 543322:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
85GF Score

Get the complete analysis for NSE:ALIVUS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,160.10
Price
₹1,007.38
GF Value